Business Context and Reporting Period
Company: China SXT Pharmaceuticals, Inc. (China SXT)
Filing Type: Form 6-K (Interim Report)
Reporting Period: Six months ended September 30, 2018 (Unaudited)
Filing Date: March 27, 2019
Business Overview: The Company manufactures and sells traditional Chinese medicine pieces (TCMP), categorized as Regular, Fine, and Advanced TCMP. Operations are primarily conducted through a Variable Interest Entity (VIE) in China.
Recent Development: The Company completed its Initial Public Offering (IPO) on December 31, 2018, and a second closing on January 3, 2019, raising approximately $10.2 million in gross proceeds.
Key Financial Metrics
| Metric | Six Months Ended Sept 30, 2018 | Six Months Ended Sept 30, 2017 |
|---|---|---|
| Revenues | $3,917,707 | $3,889,851 |
| Gross Profit | $2,678,684 | $1,658,012 |
| Gross Margin | 68.4% | 42.6% |
| Net Income | $995,046 | $787,305 |
| Net Cash Used by Operations | ($235,130) | ($547,521) |
| Cash and Cash Equivalents (Sept 30, 2018) | $217,009 | N/A |
| Total Assets (Sept 30, 2018) | $7,951,286 | $7,657,894 (Mar 31, 2018) |
| Total Current Liabilities (Sept 30, 2018) | $3,991,539 | $4,372,119 (Mar 31, 2018) |
Material Changes vs. Prior Period
- Revenue Composition Shift: While total revenue remained relatively flat (+1%), the mix shifted significantly. Advanced TCMP revenue surged 117% to $2.12 million (54% of total revenue), driven by a 52% volume increase. Conversely, Regular TCMP revenue dropped 40% to $1.62 million, largely due to the absence of a one-off $1.27 million order from a single customer in the prior year.
- Margin Expansion: Gross profit increased 62% to $2.68 million. This was driven by the higher-margin Advanced TCMP mix, a ~30% decrease in raw material costs, and improved labor efficiency.
- Operating Expenses: Total operating expenses rose 121% to $1.35 million. Selling expenses increased 285% due to higher distribution costs for remote clients and increased advertising. General and administrative expenses rose 30% due to increased R&D and intermediate service charges.
- Profitability: Net income increased 26% to $995,046, reflecting the improved gross margin despite higher operating expenses.
Guidance, Outlook, and Risks
- Liquidity Constraints: As of September 30, 2018, cash and cash equivalents were $217,009. The Company reported net cash used by operations of $235,130 for the period, though this was an improvement over the $547,521 used in the prior year.
- Dividend Restrictions: PRC laws restrict the ability of the Company's Chinese subsidiary and VIE to transfer net assets to the parent company. Dividends can only be paid from retained earnings determined under PRC GAAP, and 10% of after-tax profits must be appropriated to a statutory reserve fund until it reaches 50% of registered capital.
- Forward-Looking Statements: The filing contains forward-looking statements regarding future results and strategy. Actual results may differ materially due to risks described in the Registration Statement (Form 424B).
- Unaudited Status: Financial information is unaudited and subject to adjustment upon year-end audit.
Investor Verification Checklist
- Cash Position: Verify the current cash balance given the low cash on hand ($217k) relative to operating cash burn and the recent IPO proceeds.
- Customer Concentration: Assess the risk of revenue volatility given the significant drop in Regular TCMP sales after the loss of a single large customer in the prior period.
- Related Party Transactions: Review the $105,143 in revenue from related parties and the $205,452 in amounts due to related parties on the balance sheet.
- Dividend Policy: Confirm the practical ability to repatriate profits from the PRC subsidiary given statutory reserve requirements and regulatory restrictions.
- Inventory Levels: Monitor inventory levels ($1.07 million) relative to sales velocity, particularly for the high-growth Advanced TCMP line.